Trend Following
(11)
▼
Momentum
(6)
▼
Volatility
(5)
▼
Pattern Recognition
(5)
▼
Mean Reversion
(4)
▼
Volume Based
(5)
▼
Advanced
(10)
▼
INKT
$11.47
$
MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. MiNK Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.
Next Earnings
2026-02-25
Beta
0.345
Average Volume
Market Cap
Last Dividend
CIK
0001840229
ISIN
US6036932019
CUSIP
603693201
CEO
Jennifer S. Buell
Sector
Healthcare
Industry
Biotechnology
Full Time Employees
23
IPO Date
2021-10-15
Status
Active
Latest News
| Title | Headline | Publisher | Date |
|---|---|---|---|
| MiNK Therapeutics Presents New Data of allo-iNKT Cell Therapy as a Potential Disease-Modifying Approach in Idiopathic Pulmonary Fibrosis at Keystone Symposia | Human lung tissue analyses identify iNKT cell depletion as a mechanistic feature of advanced IPF Findings extend MiNK's iNKT platform into chronic fibrotic lung disease and support immune restoration strategies in IPF, a large unmet-need market LEXINGTON, Mass., Feb. 03, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics (Nasdaq: INKT) today announced that new translational data supporting the role of invariant natural killer T (iNKT) cells in idiopathic pulmonary fibrosis (IPF) were presented at the Emerging Cell Therapies Meeting of the Keystone Symposia on Molecular and Cellular Biology, taking place February 1–4, 2026, in Banff, Alberta, Canada. | GlobeNewsWire | 2026-02-03 21:30:00 |
| MiNK Therapeutics, Inc. (NASDAQ:INKT) Receives Consensus Recommendation of “Hold” from Analysts | Shares of MiNK Therapeutics, Inc. (NASDAQ: INKT - Get Free Report) have been given an average rating of "Hold" by the five research firms that are currently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, two have assigned a hold rating, one has given a buy rating and | Defense World | 2026-01-20 04:39:10 |
| MiNK Therapeutics and University of Wisconsin–Madison Announce Phase 1 Clinical Trial of Allo-iNKT Cell Therapy (AgenT-797) to Evaluate Prevention of Graft-Versus-Host Disease | NEW YORK, Jan. 08, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering off-the-shelf allogeneic invariant natural killer T (allo-iNKT) cell therapies, today announced the upcoming initiation of a Phase 1, investigator-sponsored clinical trial evaluating its lead therapy, agenT-797, in patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT). | GlobeNewsWire | 2026-01-08 12:00:00 |
| MiNK Therapeutics, Inc. (NASDAQ:INKT) Receives Consensus Rating of “Hold” from Analysts | MiNK Therapeutics, Inc. (NASDAQ: INKT - Get Free Report) has earned an average rating of "Hold" from the five research firms that are presently covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, two have issued a hold recommendation, one has assigned a buy recommendation and one has | Defense World | 2025-12-26 01:26:48 |
SEC Filings
| Type | Filing Date | Accepted Date | Link |
|---|---|---|---|
| 4/A | 2026-01-14 | 2026-01-14 | View Filing |
| 4 | 2026-01-06 | 2026-01-06 | View Filing |
| 4 | 2026-01-06 | 2026-01-06 | View Filing |
| 4 | 2026-01-06 | 2026-01-06 | View Filing |
| 4 | 2026-01-06 | 2026-01-06 | View Filing |
| 4 | 2026-01-06 | 2026-01-06 | View Filing |
| 8-K | 2026-01-02 | 2026-01-02 | View Filing |
| EFFECT | 2025-12-11 | 2025-12-12 | View Filing |
| S-3/A | 2025-12-10 | 2025-12-10 | View Filing |
| 8-K | 2025-12-08 | 2025-12-08 | View Filing |
| 4 | 2025-12-03 | 2025-12-03 | View Filing |
| 4 | 2025-12-03 | 2025-12-03 | View Filing |
| 4 | 2025-12-03 | 2025-12-03 | View Filing |
| 4 | 2025-12-03 | 2025-12-03 | View Filing |
| 4 | 2025-12-03 | 2025-12-03 | View Filing |
| 4 | 2025-12-03 | 2025-12-03 | View Filing |
| 10-Q | 2025-11-14 | 2025-11-14 | View Filing |
| S-3 | 2025-11-07 | 2025-11-07 | View Filing |
| 4/A | 2025-10-03 | 2025-10-03 | View Filing |
| 8-K | 2025-09-29 | 2025-09-29 | View Filing |
| 4 | 2025-09-11 | 2025-09-11 | View Filing |
| 4 | 2025-09-11 | 2025-09-11 | View Filing |
| 4 | 2025-09-11 | 2025-09-11 | View Filing |
| 4 | 2025-09-11 | 2025-09-11 | View Filing |
| 4 | 2025-09-11 | 2025-09-11 | View Filing |
| 4 | 2025-09-11 | 2025-09-11 | View Filing |
| 4 | 2025-09-03 | 2025-09-03 | View Filing |
| 4 | 2025-09-03 | 2025-09-03 | View Filing |
| 4 | 2025-09-03 | 2025-09-03 | View Filing |
| 4 | 2025-09-03 | 2025-09-03 | View Filing |
| 4 | 2025-09-03 | 2025-09-03 | View Filing |
| 424B5 | 2025-08-22 | 2025-08-22 | View Filing |
| S-8 | 2025-08-14 | 2025-08-14 | View Filing |
| 10-Q | 2025-08-14 | 2025-08-14 | View Filing |
| 8-K | 2025-08-14 | 2025-08-14 | View Filing |
| 8-K | 2025-07-15 | 2025-07-15 | View Filing |
| 424B5 | 2025-07-15 | 2025-07-15 | View Filing |
| 8-K | 2025-07-14 | 2025-07-14 | View Filing |
| 8-K | 2025-06-18 | 2025-06-18 | View Filing |
| 4 | 2025-06-04 | 2025-06-04 | View Filing |
| 4 | 2025-06-04 | 2025-06-04 | View Filing |
| 4 | 2025-06-04 | 2025-06-04 | View Filing |
| 4 | 2025-06-04 | 2025-06-04 | View Filing |
| 4 | 2025-06-04 | 2025-06-04 | View Filing |
| 10-Q | 2025-05-15 | 2025-05-15 | View Filing |
| 8-K | 2025-05-15 | 2025-05-15 | View Filing |
| ARS | 2025-04-30 | 2025-04-30 | View Filing |
| DEF 14A | 2025-04-30 | 2025-04-30 | View Filing |
| PRE 14A | 2025-04-18 | 2025-04-18 | View Filing |
| 10-K | 2025-03-18 | 2025-03-18 | View Filing |
| 8-K | 2025-03-18 | 2025-03-18 | View Filing |
| 4 | 2025-03-05 | 2025-03-05 | View Filing |
| 4 | 2025-03-05 | 2025-03-05 | View Filing |
| 4 | 2025-03-05 | 2025-03-05 | View Filing |
| 4 | 2025-03-05 | 2025-03-05 | View Filing |
| 4 | 2025-03-05 | 2025-03-05 | View Filing |
| 8-K | 2025-01-21 | 2025-01-21 | View Filing |
| DEF 14A | 2024-12-20 | 2024-12-20 | View Filing |
| 4 | 2024-12-09 | 2024-12-09 | View Filing |
| 3 | 2024-12-09 | 2024-12-09 | View Filing |
| PRE 14A | 2024-12-06 | 2024-12-06 | View Filing |
| 4 | 2024-12-03 | 2024-12-03 | View Filing |
| 4 | 2024-12-03 | 2024-12-03 | View Filing |
| 4 | 2024-12-03 | 2024-12-03 | View Filing |
| 4 | 2024-12-03 | 2024-12-03 | View Filing |
| 10-Q | 2024-11-14 | 2024-11-14 | View Filing |
| 8-K | 2024-11-14 | 2024-11-14 | View Filing |
| 8-K | 2024-10-31 | 2024-10-31 | View Filing |
| 8-K | 2024-10-18 | 2024-10-18 | View Filing |
| 8-K | 2024-09-13 | 2024-09-13 | View Filing |
| 4 | 2024-09-05 | 2024-09-05 | View Filing |
| 4 | 2024-09-05 | 2024-09-05 | View Filing |
| 4 | 2024-09-05 | 2024-09-05 | View Filing |
| 4 | 2024-09-05 | 2024-09-05 | View Filing |
| 8-K | 2024-08-30 | 2024-08-30 | View Filing |
| EFFECT | 2024-08-19 | 2024-08-19 | View Filing |
| 424B3 | 2024-08-16 | 2024-08-16 | View Filing |
| S-3 | 2024-08-13 | 2024-08-13 | View Filing |
| S-8 | 2024-08-13 | 2024-08-13 | View Filing |
| 10-Q | 2024-08-13 | 2024-08-13 | View Filing |
| 8-K | 2024-08-13 | 2024-08-13 | View Filing |
| 8-K | 2024-06-17 | 2024-06-17 | View Filing |
| 4 | 2024-06-05 | 2024-06-05 | View Filing |
| 4 | 2024-06-05 | 2024-06-05 | View Filing |
| 4 | 2024-06-05 | 2024-06-05 | View Filing |
| 4 | 2024-06-05 | 2024-06-05 | View Filing |
| SC 13G | 2024-05-22 | 2024-05-22 | View Filing |
| 8-K | 2024-05-16 | 2024-05-16 | View Filing |
| 8-K | 2024-05-14 | 2024-05-14 | View Filing |
| 10-Q | 2024-05-14 | 2024-05-14 | View Filing |
| ARS | 2024-04-30 | 2024-04-29 | View Filing |
| DEF 14A | 2024-04-29 | 2024-04-29 | View Filing |
| 10-K | 2024-03-21 | 2024-03-21 | View Filing |
| 8-K | 2024-03-21 | 2024-03-21 | View Filing |
| 4 | 2024-03-05 | 2024-03-05 | View Filing |
| 4 | 2024-03-05 | 2024-03-05 | View Filing |
| 4 | 2024-03-05 | 2024-03-05 | View Filing |
| 4 | 2024-03-05 | 2024-03-05 | View Filing |
| 8-K | 2024-02-29 | 2024-02-29 | View Filing |
Algorithm Performance
Upgrade To Premium for Full Access
| Algorithm | Profit/Loss | Profit Factor | # Trades | Sharpe | Sortino | Efficiency |
|---|---|---|---|---|---|---|
| RSI Overbought Strategy | 7.62% | 0.97 | 2 | 0.46 | 5.48 | 15.81 |
| Heikin Ashi Strategy | 6.82% | 0.98 | 8 | 0.45 | 0.38 | 15.01 |
| Pivot Points Strategy | 6.27% | 0.97 | 13 | 0.62 | 0.36 | 14.47 |
| xxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xx | xxxx | xxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xx | xxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxx | xxxx | xxxx |
| xxxxxxxxxxxxx | xxxxxx% | x | x | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxx | xxxxxxx% | x | xx | xxxx | xxx | xxxxx |
| xxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | x |
| xxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | x |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xx | xxxx | xxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xx | xxxx | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xx | xxxx | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xx | xxxx | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxxx | xxxx | xxxxx |
| xxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxx | xxxxxxx% | xxxx | x | xxxx | xxxx | xxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxx | xxxx |
| xxxxxxxxxxxxxx | xxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xx | xxxx | xxxx | xxxx |
| xxxxxxxxx | xxxxxx% | x | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | x | xxxx | xxxx | xxxx |
| xxx | xxxxx% | x | xx | xxxx | xxx | x |
| xxxxxxxxx | xxxxxx% | x | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxx |
| xxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxx |
| xxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxx |
| xxx | x% | x | x | x | x | xxx |
| xxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxx |
| xxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxx |
| xxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xx | xxxxx | x | xxxx |
| xxxxxxxxxxxx | xxxxxx% | xxxx | x | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxx | xxxxxxx% | x | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xx | xxxxx | xxxxx | xxxx |
| xxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxx |
| xxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxx | xxxxx | xxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxx | xxxxx | xxx |
| xxxxxxxxxxxxxxxx | xxxxxxxx% | xxx | x | xxxxx | xxxxx | xxxx |
| xxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | x |
| xxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxx |
| xxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxx |